Amplification and/or overexpression ofErbB2 occurs in 20–34% of invasive breast cancers [2, 3]; it is associatedwith increased cell proliferation, enhanced angiogenesis, decreased apoptosisof tumor cells, and, as a result, with a high metastasis potential [4, 5].Overexpression of ErbB2 is considered an independent prognostic factor thatdenotes an increased risk of disease recurrence. This evidence concerns the gene ERBB2 and neoplasm.